on 09-30-201409:37 AM - edited on 10-15-202105:01 AM by Closed Account
Van Assche R, Temmerman L, Dias DA, Boughton B, Boonen K, Braeckman BP, Schoofs L, Roessner U DOI 10.1007/s11306-014-0711-5 Despite decades of research, no early-onset biomarkers are currently available for Alzheimer’s disease, a cureless neurodegenerative disease afflicting millions worldwide. In this study, transgenic Caenorhabditis elegans were used to investigate changes in the metabolome after induced expression of amyloid-b. GC- and LC–MS based platforms determined a total of 157 differential features. Some of these were identified using in-house (GC–MS) or public libraries (LC–MS), revealing changes in allantoin, cystathionine and tyrosine levels. Since C. elegans is far better suited to metabolomics studies than most other model systems, the accordance of these findings with vertebrate literature is promising and argues for further use of C. elegans as a model of human pathology in the study of AD.